AdaptiSPECT-C: A Next-Generation, Adaptive Brain-Imaging SPECT System for Drug Discovery and Clinical Imaging

AdaptiSPECT-C：用于药物发现和临床成像的下一代自适应脑成像 SPECT 系统

基本信息

批准号：
9989858
负责人：
LARS R FURENLID
金额：
$ 95.38万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9989858
关键词：
3-Dimensional Anatomy Arizona Biological Markers Biomedical Research Brain Brain Diseases Brain imaging Calibration Characteristics Clinic Clinical Clinical Data Code Collimator Computer software Contracts Data Dementia Detection Development Diagnostic Differential Diagnosis Discipline of Nuclear Medicine Disease Distributional Activity Documentation Drug Industry Drug Kinetics FDA approved Face Gamma Rays Generations Geometry Head Human Image Image Analysis Imaging Device Inflammation Institution Kinetics Label Lead Lesion Magnetic Resonance Imaging Maps Massachusetts Mechanics Modeling Monitor Motion Names Patient Care Patients Performance Pharmacologic Substance Phase Photons Positron-Emission Tomography Protocols documentation Radiation Dose Unit Radioisotopes Radionuclide Imaging Radiopharmaceuticals Research Contracts Resolution Rotation Safety Sampling Self-Correction Sensory Receptors Slice Specificity Structure Surface System Systems Analysis Testing Therapy Evaluation Tracer Universities Variant attenuation base biomarker development clinical application clinical imaging commercialization cost design detector diagnosis evaluation drug discovery flexibility human imaging human subject imaging agent imaging system improved individual patient innovation kinetic model molecular imaging next generation novel therapeutics performance tests pre-clinical prototype quantitative imaging reconstruction response single photon emission computed tomography tool

项目摘要

Advances in molecular imaging are yielding a new generation of single-photon-emission-computed- tomography (SPECT) brain-imaging agents that will lead the way in understanding the human brain by enabling the development of biomarkers with unprecedented specificity for mapping neuroreceptors and proteinopathies associated with disease and dementia. SPECT is an ideal tracer-imaging tool for investigating the underlying mechanisms in brain disorders, their differential diagnoses, and monitoring their treatment because of its lower cost and radiation dose relative to PET, longer half-lives of the radionuclides imaged, and ability to simultaneously image multiple imaging agents labeled with different radionuclides. However, most clinical brain SPECT is still being performed by 2-headed systems with collimators designed for planar scintigraphy. To meet the potential for better patient care offered by these new imaging agents, and vastly improve the utility of existing agents, a revolution in SPECT brain-imaging system design is required. In Phase 1 of this Biomedical Research Partnership (BRP) application we propose to meet this requirement by creating a multi-detector-module multi-pinhole (MPH) SPECT brain-imaging system ideally suited for quantitative dynamic and high-spatial-resolution static SPECT imaging. Based on its heritage and intent for clinical imaging, we have named this proposed system AdaptiSPECT-C. Dynamic imaging will be enabled by obtaining sufficient angular sampling without the need for rotation. The system will automatically adapt its imaging characteristics (aperture size and number of pinholes open for imaging) in response to the imaging tasks and individual patients. It will thereby optimize lesion detection and quantification, as well as provide optimal data for pharmacokinetic analysis within structures throughout the brain. Automatic alignment to existent CT diagnostic studies of the patient for use in providing anatomical correlation, formation of attenuation maps, and templates for PVE correction will be enabled through usage of depth- sensing cameras, which will also be used for correction for head motion. Comparison of AdaptiSPECT-C to clinical systems will be conducted through inviCRO, one of the nation's top contract research organizations (CROs) serving the pharmaceutical industry. These studies will provide the documentation of system performance necessary to enable “Big-Pharma” companies to use the system to gather the clinical data necessary for FDA approval of new pharmaceuticals. Our Specific Aims are: 1. Construct an adaptable brain-SPECT system and test performance versus design specifications; 2. Develop reconstruction software for optimal image quality and activity quantification; 3.Integrate depth-sensing camera imaging to correct patient motion and align existent CT slices; and 4. Incorporate analysis software, and validate system through prototype human imaging.

分子成像的进步正在产生新一代的单光子发射计算技术断层扫描 (SPECT) 大脑成像剂将引领理解人类大脑的道路能够开发具有前所未有的特异性的生物标志物，用于绘制神经感受器和 SPECT 是一种理想的示踪成像工具。研究脑部疾病的潜在机制、鉴别诊断以及监测治疗，因为其成本较低，辐射相对剂量低于 PET，放射性核素的半衰期较长成像，并能够同时对用不同放射性核素标记的多种成像剂进行成像。然而，大多数临床脑部 SPECT 仍然由带有设计的准直器的 2 头系统执行为了满足这些新成像剂提供更好的患者护理的潜力，并极大地提高现有代理的实用性，SPECT 脑成像系统设计的一场革命正在到来必需的。在生物医学研究合作伙伴关系 (BRP) 申请的第一阶段，我们建议满足这一要求通过创建理想的多探测器模块多针孔 (MPH) SPECT 脑成像系统来满足要求基于其传统和特点，适用于定量动态和高空间分辨率静态 SPECT 成像。为了临床成像，我们将这个提议的系统命名为 AdaptiSPECT-C 动态成像。通过获得足够的角度采样而无需旋转，系统将自动启用。调整其成像特性（孔径大小和用于成像的针孔数量）以响应它将优化病变检测和量化，从而优化成像任务和个体患者。为整个大脑结构内的药代动力学分析提供最佳数据。与患者现有的 CT 诊断研究保持一致，用于提供解剖相关性，衰减图的形成以及 PVE 校正的模板将通过使用深度来启用传感摄像头，也将用于对 AdaptiSPECT-C 与头部运动进行校正。临床系统将通过美国顶级合同研究组织之一的 inviCRO 进行（CRO）为制药行业服务，这些研究将提供系统文档。使“大型制药”公司能够使用该系统收集临床数据所需的性能 FDA 批准新药品所必需的。我们的具体目标是： 1. 构建一个适应性强的大脑 SPECT 系统并测试性能与设计规范；2.开发重建软件以实现最佳图像质量和活动 3. 集成深度传感相机成像以纠正患者运动并对齐存在 CT 切片；和 4. 合并分析软件，并通过原型人体成像验证系统。